Intensity Therapeutics Inc
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Intensity Therapeutics stock with a target price of $6.25, indicating growth potential.
Financial Health
Intensity Therapeutics is maintaining moderate cash flow and book value per share, indicating stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring INTS
Social Media-Driven Short Squeeze Candidates
This collection features companies with high short interest that could potentially experience rapid price surges if targeted by retail investors on social media. Our analysts have carefully selected these stocks based on their similarity to recent phenomena like the Opendoor Technologies rally. These companies have the characteristics that often attract coordinated buying campaigns.
Published: July 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Platform technology potential
The company’s delivery‑focused platform is positioned to enhance oncology treatments if validated, though clinical proof is uncertain and outcomes may vary.
Clinical catalysts ahead
Trial readouts, partnerships or regulatory news can sharply move the share price; these events are binary and can lead to sizeable gains or losses.
Small‑cap considerations
A market cap around $12.6m implies limited liquidity and financing risk; investors should expect potential dilution and pronounced volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
